Cambridge Antibody Technology Group plc (LSE:CAT) and its partner BASF Pharma on Monday were to unveil data from three clinical trials of D2E7, their human anti-TNF alpha monoclonal antibody, in patients with chronic rheumatoid arthritis.

The companies have been able to conclude from the studies that D2E7 is safe and reduced disease activity in a dose responsive manner when given either intravenously or subcutaneously, and that up to 80 percent of patients achieved a clinically significant response during chronic treatment.